The KPCXM18 injection
Sponsors
Kunming Pharmaceuticals, Inc.
Conditions
Acute Ischemic Stroke
Phase 2
Study of the KPCXM18 Injection for Treatment of Acute Ischemic Stroke
NCT05745311
Start: 2023-03-01End: 2024-07-30Target: 240Updated: 2023-02-28
Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke
RecruitingNCT07279493
Start: 2025-11-22End: 2026-10-18Target: 300Updated: 2025-12-12